Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells. [electronic resource]
Producer: 20190812Description: 17390 p. digitalISSN:- 2045-2322
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- Chromones -- pharmacology
- Humans
- Lung Neoplasms -- drug therapy
- Molecular Docking Simulation
- Phosphorylation
- Protein Processing, Post-Translational
- STAT1 Transcription Factor -- antagonists & inhibitors
- STAT3 Transcription Factor -- antagonists & inhibitors
- STAT5 Transcription Factor -- antagonists & inhibitors
- Structure-Activity Relationship
- Tumor Suppressor Proteins -- antagonists & inhibitors
- src Homology Domains
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.